Clinical proteomics and mass spectrometry profiling for cancer detection

被引:38
作者
Solassol, Jerome
Jacot, William
Lhermitte, Ludovic
Boulle, Nathalie
Maudelonde, Thierry
Mange, Alain
机构
[1] Hop Arnaud de Villeneuve, Biol Cellulaire Lab, INSERM, U540, F-34295 Montpellier 5, France
[2] Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France
关键词
biomarker; cancer; clinical proteomics; Clinprot (TM); SELDI-TOF;
D O I
10.1586/14789450.3.3.311
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A key challenge in the clinical proteomics of cancer is the identification of biomarkers that would enable early detection, diagnosis and monitoring of disease progression to improve long-term survival of patients. Recent advances in proteomic instrumentation and computational methodologies offer a unique chance to rapidly identify these new candidate markers or pattern of markers. The combination of retentate affinity chromatography and mass spectrometry is one of the most interesting new approaches for cancer diagnostics using proteomic profiling. This review presents two technologies in this field, surface-enhanced laser desorption/ionization time-of-flight and Clinprot(TM), and aims to summarize the results of studies obtained with the first of them for the early diagnosis of human cancer. Despite promising results, the use of the proteomic profiling as a diagnostic tool brought some controversies and technical problems, and still requires some efforts to be standardized and validated.
引用
收藏
页码:311 / 320
页数:10
相关论文
共 87 条
[51]   Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer [J].
Paweletz, CP ;
Trock, B ;
Pennanen, M ;
Tsangaris, T ;
Magnant, C ;
Liotta, LA ;
Petricoin, EF .
DISEASE MARKERS, 2001, 17 (04) :301-307
[52]  
Pearl DC, 2002, LANCET, V360, P169, DOI 10.1016/S0140-6736(02)09388-1
[53]   Counterpoint - The vision for a new diagnostic paradigm [J].
Petricoin, E ;
Liotta, LA .
CLINICAL CHEMISTRY, 2003, 49 (08) :1276-1278
[54]   SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer [J].
Petricoin, EF ;
Liotta, LA .
CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (01) :24-30
[55]  
Petricoin EF, 2002, J NATL CANCER I, V94, P1576
[56]   Use of proteomic patterns in serum to identify ovarian cancer [J].
Petricoin, EF ;
Ardekani, AM ;
Hitt, BA ;
Levine, PJ ;
Fusaro, VA ;
Steinberg, SM ;
Mills, GB ;
Simone, C ;
Fishman, DA ;
Kohn, EC ;
Liotta, LA .
LANCET, 2002, 359 (9306) :572-577
[57]   Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma [J].
Pusztai, L ;
Gregory, BW ;
Baggerly, KA ;
Peng, B ;
Koomen, J ;
Kuerer, HM ;
Esteva, FJ ;
Symmans, WF ;
Wagner, P ;
Hortobagyi, GN ;
Laronga, C ;
Semmes, OJ ;
Wright, GL ;
Drake, RR ;
Vlahou, A .
CANCER, 2004, 100 (09) :1814-1822
[58]  
Qian HG, 2005, WORLD J GASTROENTERO, V11
[59]  
Qu YS, 2002, CLIN CHEM, V48, P1835
[60]   Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers [J].
Rai, AJ ;
Stemmer, PM ;
Zhang, Z ;
Adam, BL ;
Morgan, WT ;
Caffrey, RE ;
Podust, VN ;
Patel, M ;
Lim, LY ;
Shipulina, NV ;
Chan, DW ;
Semmes, OJ ;
Leung, HCE .
PROTEOMICS, 2005, 5 (13) :3467-3474